

David M Sansom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/720731/publications.pdf>

Version: 2024-02-01

62
papers

9,206
citations

87888

38
h-index

114465

63
g-index

68
all docs

68
docs citations

68
times ranked

12202
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of CTLA-4 recycling by LRBA and Rab11. <i>Immunology</i> , 2021, 164, 106-119.	4.4	20
2	Genomic profiling of T-cell activation suggests increased sensitivity of memory T cells to CD28 costimulation. <i>Genes and Immunity</i> , 2020, 21, 390-408.	4.1	17
3	CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4. <i>Frontiers in Immunology</i> , 2020, 11, 600000.	4.8	43
4	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. <i>Nature</i> , 2020, 583, 90-95.	27.8	148
5	CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis. <i>Frontiers in Immunology</i> , 2020, 11, 577655.	4.8	19
6	Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis. <i>Nature Communications</i> , 2019, 10, 3106.	12.8	48
7	CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells. <i>Science Immunology</i> , 2019, 4, .	11.9	100
8	Dimers Aren't Forever: CD80 Breaks up with PD-L1. <i>Immunity</i> , 2019, 51, 972-974.	14.3	8
9	Measuring CTLA-4-Dependent Suppressive Function in Regulatory T Cells. <i>Methods in Molecular Biology</i> , 2019, 1899, 87-101.	0.9	13
10	Study of an extended family with CTLA-4 deficiency suggests a CD28/CTLA-4 independent mechanism responsible for differences in disease manifestations and severity. <i>Clinical Immunology</i> , 2018, 188, 94-102.	3.2	30
11	Decreased sensitivity to 1,25-dihydroxyvitamin D3 in T cells from the rheumatoid joint. <i>Journal of Autoimmunity</i> , 2018, 88, 50-60.	6.5	23
12	CTLA-4: a moving target in immunotherapy. <i>Blood</i> , 2018, 131, 58-67.	1.4	704
13	Characterization of CTLA4 Trafficking and Implications for Its Function. <i>Biophysical Journal</i> , 2018, 115, 1330-1343.	0.5	63
14	Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1932-1946.	2.9	344
15	Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations. <i>Blood</i> , 2017, 129, 1458-1468.	1.4	102
16	Thymus transplantation for complete DiGeorge syndrome: European experience. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1660-1670.e16.	2.9	108
17	Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations. <i>Clinical and Experimental Immunology</i> , 2017, 190, 1-7.	2.6	123
18	Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. <i>Scientific Reports</i> , 2017, 7, 7652.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1043-1046.e5.	2.9	24
20	A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding. <i>Journal of Immunology</i> , 2017, 198, 528-537.	0.8	14
21	INCORPORATING GENETICS INTO STUDIES OF THE IMMUNOLOGY OF ARTHRITIS. <i>Rheumatology</i> , 2017, 56,19		0
22	Hematopoietic stem cell transplantation for CTLA4 deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 615-619.e1.	2.9	88
23	Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function. <i>PLoS ONE</i> , 2015, 10, e0131539.	2.5	43
24	CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 524-529.	7.1	167
25	A Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T Cells. <i>Journal of Immunology</i> , 2015, 194, 2148-2159.	0.8	97
26	Confusing signals: Recent progress in CTLA-4 biology. <i>Trends in Immunology</i> , 2015, 36, 63-70.	6.8	313
27	Moving CTLA-4 from the trash to recycling. <i>Science</i> , 2015, 349, 377-378.	12.6	29
28	Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). <i>Thorax</i> , 2015, 70, 617-624.	5.6	258
29	1,25(OH)2D3 Promotes the Efficacy of CD28 Costimulation Blockade by Abatacept. <i>Journal of Immunology</i> , 2015, 195, 2657-2665.	0.8	17
30	Follicular helper T cell signature in type 1 diabetes. <i>Journal of Clinical Investigation</i> , 2015, 125, 292-303.	8.2	143
31	A Transendocytosis Perspective on the CD28/CTLA-4 Pathway. <i>Advances in Immunology</i> , 2014, 124, 95-136.	2.2	34
32	Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. <i>Nature Medicine</i> , 2014, 20, 1410-1416.	30.7	723
33	Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade. <i>American Journal of Transplantation</i> , 2014, 14, 1985-1991.	4.7	94
34	Loss of CD28 Expression by Liver-Infiltrating T Cells Contributes to Pathogenesis of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2014, 147, 221-232.e7.	1.3	81
35	CD28 costimulation: Waking the immunological tightrope. <i>European Journal of Immunology</i> , 2013, 43, 42-45.	2.9	11
36	Regulatory T cells and COPD. <i>Thorax</i> , 2013, 68, 1176-1178.	5.6	7

#	ARTICLE	IF	CITATIONS
37	Comparison of the Intracellular Trafficking Itinerary of CTLA-4 Orthologues. PLoS ONE, 2013, 8, e60903.	2.5	13
38	Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation. Journal of Biological Chemistry, 2012, 287, 9429-9440.	3.4	131
39	Availability of 25-Hydroxyvitamin D3 to APCs Controls the Balance between Regulatory and Inflammatory T Cell Responses. Journal of Immunology, 2012, 189, 5155-5164.	0.8	172
40	Cutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells. Journal of Immunology, 2012, 189, 1118-1122.	0.8	84
41	Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. Science, 2011, 332, 600-603.	12.6	1,386
42	The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nature Reviews Immunology, 2011, 11, 852-863.	22.7	609
43	1,25-Dihydroxyvitamin D3 and IL-2 Combine to Inhibit T Cell Production of Inflammatory Cytokines and Promote Development of Regulatory T Cells Expressing CTLA-4 and FoxP3. Journal of Immunology, 2009, 183, 5458-5467.	0.8	666
44	CTLA-4 Controls Regulatory T Cell Peripheral Homeostasis and Is Required for Suppression of Pancreatic Islet Autoimmunity. Journal of Immunology, 2009, 182, 274-282.	0.8	144
45	Acquisition of Suppressive Function by Activated Human CD4+CD25 ^{hi} T Cells Is Associated with the Expression of CTLA-4 Not FoxP3. Journal of Immunology, 2008, 181, 1683-1691.	0.8	78
46	The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunological Reviews, 2006, 212, 131-148.	6.0	257
47	Integration of CD28 and CTLA-4 function results in differential responses of T _H 1 cells to CD80 and CD86. European Journal of Immunology, 2006, 36, 1413-1422.	2.9	62
48	CTLA4 gene polymorphism and autoimmunity. Immunological Reviews, 2005, 204, 102-115.	6.0	252
49	Exocytosis of CTLA-4 Is Dependent on Phospholipase D and ADP Ribosylation Factor-1 and Stimulated during Activation of Regulatory T Cells. Journal of Immunology, 2005, 174, 4803-4811.	0.8	80
50	CD86 and CD80 Differentially Modulate the Suppressive Function of Human Regulatory T Cells. Journal of Immunology, 2004, 172, 2778-2784.	0.8	243
51	What's the difference between CD80 and CD86?. Trends in Immunology, 2003, 24, 313-318.	6.8	225
52	CD28, CTLA-4 and their ligands: who does what and to whom?. Immunology, 2000, 101, 169-177.	4.4	287
53	IL-2-independent activation and proliferation in human T cells induced by CD28. Journal of Immunology, 1999, 163, 1809-16.	0.8	25
54	Phorbol esters modulate the coupling of the T cell costimulatory molecule CD28 to phosphatidylinositol 3-kinase. Biochemical Society Transactions, 1997, 25, 305S-305S.	3.4	1

#	ARTICLE	IF	CITATIONS
55	A role for RANTES in T lymphocyte proliferation. <i>Biochemical Society Transactions</i> , 1996, 24, 93S-93S.	3.4	10
56	Induction of activator protein (AP)-1 and nuclear factor-kappaB by CD28 stimulation involves both phosphatidylinositol 3-kinase and acidic sphingomyelinase signals. <i>Journal of Immunology</i> , 1996, 157, 3290-7.	0.8	42
57	The phosphoinositide 3-kinase inhibitor wortmannin inhibits CD28-mediated T cell co-stimulation. <i>Biochemical Society Transactions</i> , 1995, 23, 282S-282S.	3.4	5
58	Antibody ligation of CD7 leads to association with phosphoinositide 3-kinase and phosphatidylinositol 3,4,5-trisphosphate formation in T lymphocytes. <i>European Journal of Immunology</i> , 1995, 25, 502-507.	2.9	24
59	B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells <i>in vitro</i> . <i>European Journal of Immunology</i> , 1993, 23, 295-298.	2.9	110
60	Ligation of CD28 receptor by B7 induces formation of D-3 phosphoinositides in T lymphocytes independently of T cell receptor/CD3 activation. <i>European Journal of Immunology</i> , 1993, 23, 2572-2577.	2.9	119
61	EMOTIONAL AND BEHAVIOURAL ASPECTS OF RETT SYNDROME. <i>Developmental Medicine and Child Neurology</i> , 1993, 35, 340-345.	2.1	74
62	B7/CD28 but not LFA-3/CD2 interactions can provide 'third-party' co-stimulation for human T-cell activation. <i>Immunology</i> , 1993, 80, 242-7.	4.4	27